Patients with a history of a different malignancy are excluded, unless the disease has not progressed for >= 2 yearsXx_NEWLINE_xXPrevious therapy with anthracyclines or taxanes for any malignancyXx_NEWLINE_xXPatient must not have a concurrent active malignancy for which they are receiving treatmentXx_NEWLINE_xXPrior or current invasive malignancy with current evidence of active disease within the past 3 yearsXx_NEWLINE_xXNo other active malignancy that the investigator determines would interfere with the treatment and safety analysisXx_NEWLINE_xXPatients with a history of any malignancy are ineligibleXx_NEWLINE_xXPatients who previously received endocrine therapy within 5 years prior to diagnosis of the current malignancy.Xx_NEWLINE_xXPrior malignancy other than acute leukemia is allowed, provided it is in remission and there is no plan to treat the malignancy at the time of registrationXx_NEWLINE_xXIndividuals with a history of a malignancy (other than multiple myeloma) are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXOther invasive malignancy within 2 years.Xx_NEWLINE_xXParticipants with other active malignancy requiring concurrent interventionXx_NEWLINE_xXPrior malignancyXx_NEWLINE_xXOther active malignancy requiring concurrent interventionXx_NEWLINE_xXHistory of prior malignancy, except (Criteria a through f):Xx_NEWLINE_xXAny known additional malignancy that is progressing or required active treatment in the last 3 yearsXx_NEWLINE_xXKnown history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.Xx_NEWLINE_xXHistory of other malignancy within 2 years prior to screeningXx_NEWLINE_xXHistory of malignancy other than gastric or gastroesophageal junction carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death;Xx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXSubjects with other active malignancy requiring concurrent interventionXx_NEWLINE_xXOther active malignancy that is progressing, requires concurrent intervention, and/or could be mistaken for the malignancy under study during disease assessmentsXx_NEWLINE_xXActive malignancy (other than BRAF V600 mutation-negative melanoma) or malignancy within 3 yearsXx_NEWLINE_xXParticipants with other active malignancy in the past 3 years excluding in situ tumorsXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXKnown history of another primary malignancy that has not been in remission for ?1 yearXx_NEWLINE_xXAny other current or previous malignancy within 3 years except protocol allowed malignanciesXx_NEWLINE_xXHistory of other malignancy unless the subject has been disease-free for at least 3 yearsXx_NEWLINE_xXSubject must have histological or cytological evidence of a solid malignancyXx_NEWLINE_xXPatients being actively treated for a secondary malignancyXx_NEWLINE_xXConfirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:Xx_NEWLINE_xXActive secondary malignancyXx_NEWLINE_xXReceived previous therapy for malignancy within 21 daysXx_NEWLINE_xXOther malignancy within 2 years prior to entry into the study, except for those treated with surgical therapy only (e.g., localized low-grade cervical or prostate cancers).Xx_NEWLINE_xXOther prior malignancy active within the previous 3 years except for local or organ confined early stage cancer that has been definitively treated with curative intent, does not require ongoing treatment, has no evidence of residual disease and has a negligible risk of recurrence and is therefore unlikely to interfere with the primary and secondary endpoints of the study, including response rate and safetyXx_NEWLINE_xXDiagnosis of relapsed or refractory lymphoid malignancy for which there are no available therapies.Xx_NEWLINE_xXHistory of prior malignancy unless disease free for > or equal to 12 months or considered surgically cured.Xx_NEWLINE_xXSecondary malignancy.Xx_NEWLINE_xXPatients who have been diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease are not eligible; NOTE: patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients who have an option for any treatment with proven clinical benefit for their lymphoid malignancy at current state of disease.Xx_NEWLINE_xXPast or present malignancy within the last 5 years.Xx_NEWLINE_xXConcurrent active malignancy requiring immediate therapyXx_NEWLINE_xXA patient with a known other malignancy is eligible if there is a negligible risk for disease progression or death within one year, there is no active ongoing treatment for this malignancy, and the malignancy and/or any anticipated future treatments would not interfere with protocol-mandated evaluations at 1 yearXx_NEWLINE_xXPatients with a prior malignancy will NOT be eligible for participation aside from the following exception:\r\n* Patients who have had any curatively treated invasive malignancy and have been disease free without treatment for 1 year prior to study entry ARE eligible for participationXx_NEWLINE_xXBRAF V600 mutation-positive malignancyXx_NEWLINE_xXPts receiving active treatment or intervention for any other malignancy or pts who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.Xx_NEWLINE_xXHistory of another malignancy within 3 years of the first dose of study drug, or any evidence of residual disease from a previously diagnosed malignancy.Xx_NEWLINE_xXActive malignancy other than the one for which AB-110 transplant is being performed within 12 months of enrollment.Xx_NEWLINE_xXIndividuals with a history of different malignancy are ineligible except for the following circumstances. Individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the principal investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXParticipants with other active malignancy requiring concurrent interventionXx_NEWLINE_xXHave a primary CNS malignancy (eg, GBM).Xx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatment within the past 5 years.Xx_NEWLINE_xXParticipants with any other active malignancy requiring concurrent interventionXx_NEWLINE_xXHistory of malignancy other than MM within the past 3 yearsXx_NEWLINE_xXActive cerebral/meningeal disease related to the underlying malignancyXx_NEWLINE_xXPrior anti-cancer therapies for current malignancyXx_NEWLINE_xXOther active malignancy that warrants systemic therapyXx_NEWLINE_xXPrevious therapy with anthracyclines or taxanes for any malignancy.Xx_NEWLINE_xXPrevious therapy with anthracyclines or taxanes for any malignancyXx_NEWLINE_xXHistory of other malignancy within 5 years prior to screening, with the exception of those with a negligible risk of metastasis or deathXx_NEWLINE_xXIndividuals with a history of different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXA prior or concurrent metastatic second malignancy within 3 years, even if it does not require active therapy; for example, patients with concomitant indolent B-cell malignancies will not be eligible; patients with a prior resected in-situ or stage I malignancy felt to be cured will be eligibleXx_NEWLINE_xXHas a history of a second malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 2 years.Xx_NEWLINE_xXUncontrolled concurrent malignancy (early stage is allowed if not requiring active therapy or intervention)Xx_NEWLINE_xXPrior or concurrent malignancy with known RAS mutationXx_NEWLINE_xXSteroid refractory cGvHD occurring after a non-scheduled donor lymphocyte infusion (DLI) administered for preemptive treatment of malignancy recurrence. Participants who have received a scheduled DLI as part of their transplant procedure and not for management of malignancy relapse are eligibleXx_NEWLINE_xXPatients with suspected non-gynecologic malignancy, such as gastrointestinalXx_NEWLINE_xXSubject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illnessXx_NEWLINE_xXPresence of an active hematological malignancy.Xx_NEWLINE_xXPresence of concurrent non-solid malignancyXx_NEWLINE_xXHistory of malignancy other than B-NHL within the past 3 years with the exception of:Xx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease present for ? 3 years before enrollmentXx_NEWLINE_xXHas a known history of prior malignancy except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.Xx_NEWLINE_xXPart B: Must have a type of malignancy that is being studied.Xx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXTreatment naive for his or her newly diagnosed malignancy for enrollment to groups 1 or 2Xx_NEWLINE_xXHistory of other active malignancy within past 2 years.Xx_NEWLINE_xXEvidence of relapse or progression of hematologic malignancy at the time of study enrollment.Xx_NEWLINE_xXPersistence/relapse at the time of study entry of the primary malignancy for which the transplant was performed, or any other active malignancy; patients with a history of relapsed malignancy who have achieved a remission at the time of evaluation for study participation will not be excludedXx_NEWLINE_xXPatients with concurrent malignancy except for nonmelanoma skin lesionsXx_NEWLINE_xXNo other history of or ongoing malignancy that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assayXx_NEWLINE_xXDiagnosed or treated for another malignancy within 5 years before randomization or previous diagnosis with another malignancy. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXActive concurrent malignancy requiring active therapyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients must NOT have an active malignancy other than CD19+ leukemiaXx_NEWLINE_xXPrior invasive malignancy of other histology currently requiring treatmentXx_NEWLINE_xXDiagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPrevious or concurrent additional malignancyXx_NEWLINE_xXIn patients with a prior history of invasive malignancy, less than five years in complete remissionXx_NEWLINE_xXPresence of another malignancy requiring current treatment that would preclude the use of all of the study treatments or the ability to monitor the natural history of MCD untreatedXx_NEWLINE_xXPrevious malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessmentXx_NEWLINE_xXAdvanced measurable malignancyXx_NEWLINE_xXPatient is ? 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active interventionXx_NEWLINE_xXPatients must have had histologic or flow cytometric verification of the malignancy at relapseXx_NEWLINE_xXPrevious malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessmentXx_NEWLINE_xXNo evidence of malignancy at the time of enrollmentXx_NEWLINE_xXPrior other malignancy within 2 years (except for in situ disease, which is permissible).Xx_NEWLINE_xXNo evidence of an active malignancy that would limit the patient’s survival to less than 2 years. (If there is any question, the principal investigator [PI] can make a decision).Xx_NEWLINE_xXPatient must not have a concurrent active malignancy for which they are receiving treatmentXx_NEWLINE_xXPatients with a concurrent active malignancy under treatment.Xx_NEWLINE_xXPatients who have a history of another primary malignancy that has been diagnosed or required therapy within 3 years before randomization.Xx_NEWLINE_xXHas received prior sunitinib or pembrolizumab therapy for the treatment of malignancyXx_NEWLINE_xXAny active malignancy other than DLBCLXx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXKnown additional malignancy that is active and/or progressive requiring treatment; subjects with other malignancies that have been definitively treated and who have been rendered disease free will be eligible.Xx_NEWLINE_xXParticipants with other active malignancy requiring concurrent interventionXx_NEWLINE_xXOther active malignancyXx_NEWLINE_xXHistory of another malignancy except for:Xx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease > 5 years prior to the start of CMP-001 dosing on W1D1 and of low potential risk for recurrence.Xx_NEWLINE_xXActive second malignancy, i.e. patient known to have potentially fatal cancer present for which he/she may be (but not necessarily) currently receiving treatment; patients with a history of malignancy that has been completely treated, with no evidence of that cancer currently, are permitted to enroll in the trial provided all chemotherapy for prior malignancy was completed > 12 months prior and/or bone marrow transplant > 2 years priorXx_NEWLINE_xXT-cell malignancyXx_NEWLINE_xXOther active malignancy requiring concurrent interventionXx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatment within 3 years of start of study drug.Xx_NEWLINE_xXPresence of any other concurrent active malignancyXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients with a history of another invasive malignancy within the last 3 yearsXx_NEWLINE_xXDiagnosis or treated for another malignancy within 2 years before enrollment, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any time are not excluded if they have undergone resectionXx_NEWLINE_xXActive malignancy (other than melanoma) or a prior malignancy within the past 3 yearsXx_NEWLINE_xXPrior malignancy (other than breast cancer) unless diagnosed and definitively treated more than 5 years prior to randomization.Xx_NEWLINE_xXPrior therapy for glioblastoma or other invasive malignancyXx_NEWLINE_xXOther malignancy requiring treatment in the prior 2 yearsXx_NEWLINE_xXNo active secondary malignancyXx_NEWLINE_xXCold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancyXx_NEWLINE_xXHistory of malignancy other than NSCLC within 2 years prior to screeningXx_NEWLINE_xXParticipants must not have other active malignancy requiring concurrent interventionXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resectionXx_NEWLINE_xXSubjects must NOT have an active malignancy other than CD19+CD22+ leukemiaXx_NEWLINE_xXPatients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.Xx_NEWLINE_xXKnown history of an additional malignancy, except if the participant has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.Xx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXEvidence of another malignancy, exclusive of a skin cancer that requires only local treatmentXx_NEWLINE_xXIndividuals with a history of different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 3 years or are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXHas had known additional malignancy that is progressing or requires active treatment, or history of other malignancy within 2 years of study entry.Xx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXHave a history of another primary malignancy, with the exception of:Xx_NEWLINE_xXIs diagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease.Xx_NEWLINE_xXOther active malignancy requiring concurrent intervention.Xx_NEWLINE_xXHas history of other active malignancy within 3 years prior to enrollment, except:Xx_NEWLINE_xXKnown additional malignancy that requires active systemic treatmentXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXSubjects must NOT have an active malignancy other than CD22+ leukemiaXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXRadiographically measurable lymphadenopathy or extranodal lymphoid malignancy.Xx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXPatient has malignancy or life-threatening systemic disease or a history of advanced, serious, life-threatening malignancy/disease within the last 5 years, except very low-risk prostate cancerXx_NEWLINE_xXDiagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy; malignancy felt by investigator to potentially affect subject survival or ability to evaluate disease responseXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXConcurrent malignancy requiring cytotoxic or immunotherapy based treatmentXx_NEWLINE_xXPatients must not have received treatment for another malignancy within 3 years of enrollmentXx_NEWLINE_xXEvidence of active malignancy other than CD19+ malignancyXx_NEWLINE_xXDiagnosed with or treated for another malignancy within 2 years before randomization, or previously diagnosed with another malignancy and have any evidence of residual, persistent, or recurrent disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXAny history of or current hematologic malignancyXx_NEWLINE_xXPrior malignancy or therapy for a malignancy within 3 yearsXx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXSubject has any other active malignancy besides the tumor under study within 3 years prior to Screening. Subject has uncontrolled intercurrent illness.Xx_NEWLINE_xXParticipants with presence of other active malignancy within 2 years of study entry; participants with history of prior malignancy treated with curative intent and achieved CR within 2 years are eligible.Xx_NEWLINE_xXConcurrent active malignancy that requires systemic treatmentXx_NEWLINE_xXOther active malignancy receiving systemic therapy.Xx_NEWLINE_xXOther active malignancy requiring concurrent intervention; a history of prior malignancy will not be an exclusion factor as long as the patient is not currently requiring treatment for this malignancyXx_NEWLINE_xXActive malignancyXx_NEWLINE_xXNo active or co-existing malignancy requiring chemotherapy or radiation within 6 monthsXx_NEWLINE_xXHave a known additional malignancy that is progressing or required active treatment within the past 1 year.Xx_NEWLINE_xXHas positive urine cytology for urothelial malignancy at screening.Xx_NEWLINE_xXConcurrent hematologic or non-hematologic malignancy requiring treatmentXx_NEWLINE_xXThe presence of any other concurrent active malignancyXx_NEWLINE_xXPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.Xx_NEWLINE_xXPatients with concurrent second malignancy. Persons with previous malignancies effectively treated and not requiring treatment for >24 months are eligible, provided there is unambiguous documentation that current local recurrence or metastatic site represents recurrence of the primary breast malignancy.Xx_NEWLINE_xXPatients may have received chemotherapy or radiation for a previous, curatively treated malignancy provided at least 2 years have elapsed and there is no current evidence of disease (patients with previous or concurrent additional skin cancers will be eligible); patients with chronic lymphoid or leukemic malignancies are eligible with or without active disease as long as they have not had treatment within the past three monthsXx_NEWLINE_xXMALIGNANCY CRITERIA:Xx_NEWLINE_xXActive CNS malignancyXx_NEWLINE_xXDiagnosed with another concurrent malignancy requiring treatmentXx_NEWLINE_xXNo previous cancer treatment with any cytotoxic agent for this malignancyXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXHave active malignancy with the exception of nonmelanoma skin cancer, as determined by the investigator. Subjects who experience relapse or progression of their underlying malignancy (for which HSCT was performed), as determined by the investigator, are not to be enrolled.Xx_NEWLINE_xXOther malignancy within 2 years prior to screening, with some exceptionsXx_NEWLINE_xXActive cerebral/meningeal disease related to the underlying malignancyXx_NEWLINE_xXHistologic/molecular diagnosis of malignancy at diagnosis or the time of relapseXx_NEWLINE_xXActive malignancy besides NSCLC within 3 years prior to screening.Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXDiagnosed or treated for another malignancy =< 2 years prior to registration or previously diagnosed with another malignancy and have any evidence of residual disease; NOTE: Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXConcurrent malignancy or malignancy within 3 years prior to starting study drug, except\r\n* Malignancies that have completed therapy and are considered by their physician to be at less than 30% risk of relapse, or\r\n* Malignancies not requiring treatment (e.g., RAI stage 0 chronic lymphocytic leukemia [CLL])Xx_NEWLINE_xXNo prior history of malignancy within 2 years, unless cured of a skin cancer or a stage I-III solid tumor; no prior hematologic malignancy within 3 yearsXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXSubjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed > 2 years ago that has undergone potentially curative therapy with no evidence of disease for the last >= 2 years and that is deemed by the investigator to be at a low risk of recurrenceXx_NEWLINE_xXHistory of malignancy other than their lymphoma with the exception of:Xx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease present for ? 3 years before enrollment and felt to be at low risk for recurrence by the treating physician.Xx_NEWLINE_xXPatients must be diagnosed with a high-risk and/or advanced hematologic malignancy defined as one of the followingXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatment; patients with a stage I-III cancer that has been cured over two years ago are not excluded in the studyXx_NEWLINE_xXHas known active additional malignancy that is undergoing active treatmentXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPresence of an active hematological malignancy:Xx_NEWLINE_xXActive second malignancy or other prior malignancy treated with chemotherapy less than or equal to 6 months prior to treatment with CK-101Xx_NEWLINE_xXNo evidence of an active malignancy that would limit the patient’s survival to less than 2 years. (If there is any question, the principal investigator [PI] can make a decision)Xx_NEWLINE_xXPresence of relapsed primary malignancy, or who have been treated for relapse after the alloHSCT was performed, or who may require rapid immune suppression withdrawal as pre-emergent treatment of early malignancy relapse.Xx_NEWLINE_xXImmunosuppression, not related to prior treatment for malignancy.Xx_NEWLINE_xXPatients must not have current evidence of another malignancy that requires treatmentXx_NEWLINE_xXHistologic confirmation of malignancyXx_NEWLINE_xXDoes not have any other active malignancy other than the one for which this transplant is indicatedXx_NEWLINE_xXHematologic malignancyXx_NEWLINE_xXPathologically proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; patients with metastasis of unknown primary tumor are permittedXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPrevious malignancy is not an exclusion provided that the other malignancy is considered under control, patient is not on concomitant anti-cancer drug therapy, and target lesions from melanoma are clearly defined for response assessmentXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients with history of hematologic malignancyXx_NEWLINE_xXHas a history of another malignancy.Xx_NEWLINE_xXActive treatment of a separate malignancyXx_NEWLINE_xXDiagnosis of breast malignancyXx_NEWLINE_xXPatients with prior malignancy and treated with no evidence of active disease, and more than 2 years from initial diagnosis are eligibleXx_NEWLINE_xXPatients must have a confirmed recurrent/progressive brain malignancy that have failed at least one prior treatment regimenXx_NEWLINE_xXPresence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for esophageal cancer as determined by the treating physicianXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXA history of other malignancy with the exception of those treated with curative intent with no evidence of disease for 2 yearsXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study drug administration (exceptions are superficial skin cancers, or any in situ cancers deemed surgically resected, cured and not requiring systemic therapy, and indolent malignancies that currently do not require treatment)Xx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study administration (exceptions are superficial skin cancers, or any in situ cancers deemed surgically resected, cured and not requiring systemic therapy)Xx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Diagnosis of concurrent malignancy or previous malignancy within 3 years before study drug administration (exceptions are superficial skin cancers, or any in situ cancers deemed curatively treated and without evidence of disease for more than 3 years before regorafenib treatment)Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocolXx_NEWLINE_xXHistory of other malignancy within the last 3 years (with exceptions).Xx_NEWLINE_xXParticipants with a history of other malignancy within 5 years prior to screeningXx_NEWLINE_xXPatient has a concurrent active malignancy under treatmentXx_NEWLINE_xXThe subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXPatients with malignancy that is suspected or proven to have progressed, relapsed, or be persistent since progressive, relapsed or persistent malignancy documented since BMTXx_NEWLINE_xXPatients with prior malignancy successfully treated who are currently stable and on no active treatment are eligibleXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXHas a malignancy:Xx_NEWLINE_xXEvidence of other active invasive malignancy requiring treatment other than surgery in the past 3 yearsXx_NEWLINE_xXIndividuals with a history of a different malignancy (other than acute leukemia) are ineligible except for the following circumstances:\r\n* Individuals are eligible if the different malignancy is in complete remission at time of study entryXx_NEWLINE_xXPatients with a history of a prior malignancy who have undergone potentially curative therapy with no evidence of that disease for five years, or patients who are deemed low risk for recurrence by his/her treating physician are permitted to enrollXx_NEWLINE_xXPatients with a hematologic malignancy or solid tumorXx_NEWLINE_xXPatients with more than one malignancy (hematologic or solid tumor) are eligibleXx_NEWLINE_xXAny history of or current hematologic malignancyXx_NEWLINE_xXPrevious malignancy within 2 years of the first dose of study drugs, except tumors totally resected and/or not requiring therapyXx_NEWLINE_xXA history of other malignancy =< 5 years previous which would preclude endocrine treatment of their cancerXx_NEWLINE_xXA history of other malignancy, unless treated with curative intent, and no evidence of disease for at least 2 years.Xx_NEWLINE_xXHistory of other malignancy within the past 3 years except treated with curative intent and no known active disease present and has not received chemotherapy for >= 1 year before enrollment/randomization and low risk for recurrenceXx_NEWLINE_xXPatients with active secondary malignancy unless approved by the study chairXx_NEWLINE_xXSubject has a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXNo active prior malignancy within 3 years of registration (with the exception of non-melanoma skin cancer, in-situ cancers, or Rai stage 0 chronic lymphocytic leukemia [CLL]); if patient is disease free from a prior malignancy between 3-5 years, special consideration can be requested; in these cases, if the risk of recurrence at 5 years is less than 20%, and in the opinion of the investigator the prior malignancy will not affect the patient's outcome in light of newly diagnosed pancreatic cancer, the patient may be eligible; this will require principal investigator (PI) review and approval on a case by case basis, and approval will be documented in the medical record; all patients who have been disease free from a prior malignancy for at least 5 years will be eligibleXx_NEWLINE_xXProgressive hemato-lymphoid malignancy despite conventional therapyXx_NEWLINE_xXPrior malignancy (EXCEPTION: diagnosed > 5 years ago without evidence of disease, OR treated =< 5 years ago but have a greater than 50% chance of life expectancy of >= 5 years for that malignancy)Xx_NEWLINE_xXHistory of another primary invasive malignancy that has not been definitively treated or in remission for at least 2 years; patients with non-melanoma skin cancers or with carcinomas in situ are eligible regardless of the time from diagnosis (including concomitant diagnoses); if patients have another malignancy that was treated within the last 2 years, such patients may be enrolled if the likelihood of requiring systemic therapy for this other malignancy within 2 years is less than 10%, as determined by an expert in that particular malignancy at MD Anderson Cancer Center and after consultation with the principal investigatorXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with pathologically confirmed completely resected prostate cancer no higher than stage pT2a and no biochemical relapse, or pT2c tumors involving less than 5% of the prostate and no biochemical relapse, nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPrior malignancy in past 2 years or as identified in Section 7.2 of this protocolXx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXNo active malignancy at the time of enrollment, except nonmelanoma skin cancers or carcinoma in situ; patients with a prior history of malignancy are eligible if their malignancy has been definitely treated or is in remission and does not require ongoing adjuvant or cancer-directed therapiesXx_NEWLINE_xXSubject has been diagnosed or treated for another malignancy within 3 years of enrolment, except in situ malignancy, or low-risk prostate, skin or cervix cancer after curative therapyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPrevious other malignancies unless they have undergone curative intent therapy for that malignancy and (1) have had no evidence of that disease for 5 years, and/or (2) be deemed at low risk for recurrence (less than or equal to 20% at 5 years)Xx_NEWLINE_xXOther active malignancy requiring concurrent interventionXx_NEWLINE_xXPrevious chemotherapy for any malignancy, if given within three years of registrationXx_NEWLINE_xXResearch participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligible; any history of myelodysplasia is excludedXx_NEWLINE_xXRelapsed malignancy after transplantationXx_NEWLINE_xXPatients who have a history of another primary malignancy unless the patient has been disease free for >= 3 yearsXx_NEWLINE_xXPatient does NOT have an active malignancy other than NBXx_NEWLINE_xXActive and uncontrolled relapse of malignancy.Xx_NEWLINE_xXother malignancies curatively treated with no evidence of disease for ? 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.Xx_NEWLINE_xXOther active malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatmentXx_NEWLINE_xXRemission of any acute hematologic malignancy or adequate disease control for chronic malignanciesXx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXPatients with gynecologic malignancy of low-grade serous or borderline histologyXx_NEWLINE_xXAny other active malignancyXx_NEWLINE_xXResearch participants with presence of other active malignancy; However, research participants with history of prior malignancy treated with curative intent and in complete remission are eligibleXx_NEWLINE_xXResearch participants with presence of other active malignancy; however, research participants with history of prior malignancy treated within 2 years with curative intent and in a complete remission are eligibleXx_NEWLINE_xXResearch participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent and in complete remission are eligibleXx_NEWLINE_xXConcurrent active malignancy of another typeXx_NEWLINE_xXPatients with active secondary malignancy will not be eligible unless approved by the principal investigatorXx_NEWLINE_xXActive malignancy other than HCC.Xx_NEWLINE_xXTreatment for non-hematologic malignancy greater than 6 months prior to enrollment is acceptableXx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXOther malignancy within five years, except the following may be eligible:Xx_NEWLINE_xXHistological or cytological evidence of solid malignancy.Xx_NEWLINE_xXUncontrolled, non-hematologic malignancy requiring active treatmentXx_NEWLINE_xXHistologically or genetically proven unilateral primary or metastatic active pleural malignancyXx_NEWLINE_xXOther active malignancy (other than malignancies, which the investigator determines are unlikely to interfere with treatment and safety analysis)Xx_NEWLINE_xXHematologic or lymphoid malignancyXx_NEWLINE_xXPrior history of invasive malignancy within the last 2 yearsXx_NEWLINE_xXRECIPIENT: Presence of active malignancy in another organ system other than the hematopoietic, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancyXx_NEWLINE_xXPresence of malignancy.Xx_NEWLINE_xXDoes not have any other active malignancy other than the one for which this HCT is indicatedXx_NEWLINE_xXNeoadjuvant chemotherapy for current malignancyXx_NEWLINE_xXPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocolXx_NEWLINE_xXPatients receiving active treatment or intervention for any other malignancy or patients who, at the investigator’s discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatmentXx_NEWLINE_xXOther malignancy that would interfere with the current interventionXx_NEWLINE_xXNo malignancy (other than the one treated in this study) which required radiotherapy or systemic treatment within the past 5 yearsXx_NEWLINE_xXPatients with a history of any other malignancy, except patients with a secondary brain tumor if the patient’s first malignancy has been in remission for at least 5 years from the end of treatmentXx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatment.Xx_NEWLINE_xXConfirmed diagnosis of select advanced malignancyXx_NEWLINE_xXConcurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two yearsXx_NEWLINE_xXEXCLUSION CRITERIA FOR REGISTRATION: concurrent active invasive malignancy or one previously diagnosed with a greater than 30% chance of recurrence in the next two yearsXx_NEWLINE_xXPatients with evidence of another malignancy, exclusive of a skin cancer that requires only local treatment, should not be enrolled on this protocolXx_NEWLINE_xXNon-hematopoietic malignancy where the expected survival is less than 2 yearsXx_NEWLINE_xXNo active extramedullary leukemia or known active CNS involvement by malignancy; such disease treated into remission is permittedXx_NEWLINE_xXPresence of active malignancy in another organ system other than the hematopoietic system, except when driven by viruses in which case the immune reconstitution after transplant may control the malignancyXx_NEWLINE_xXActive cerebrospinal fluid involvement with malignancy or brain metastasisXx_NEWLINE_xXPatients with concurrent malignancy except for nonmelanoma skin lesionsXx_NEWLINE_xXNo chemotherapy for a malignancy in the last 5 yearsXx_NEWLINE_xXConcurrent malignancy or history of other malignancy within the last five years except as noted aboveXx_NEWLINE_xXPatients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligibleXx_NEWLINE_xXNo active secondary malignancy; patients with other prior malignancies will be included, provided they have been disease-free for at least five yearsXx_NEWLINE_xXPatients with therapy-related AML whose prior malignancy has been in remission for at least 12 monthsXx_NEWLINE_xXResistant malignancyXx_NEWLINE_xXDyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.Xx_NEWLINE_xXSubject has another malignancy for which treatment is required.Xx_NEWLINE_xXMalignancy other than disease under study with the exception of those from which the subject has been disease-free for more than 2 years and not expected to affect the safety of the subject or the endpoints of the trial.Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXCold agglutinin syndrome secondary to infection, rheumatologic disease, or active hematologic malignancyXx_NEWLINE_xXRelapsed or progressive malignancy after transplant, post-transplant lymphoproliferative disease or any secondary malignancy diagnosed after HCTXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resectionXx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatment.Xx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXOther active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigator.Xx_NEWLINE_xXHistory of a non-lymphoid malignancy except for protocol allowed exceptionsXx_NEWLINE_xXAny malignancyXx_NEWLINE_xXPatients with any other prior malignancy are not allowed except for the following:Xx_NEWLINE_xXHistory of malignancy;Xx_NEWLINE_xXHistory of another primary malignancyXx_NEWLINE_xXHas another active systemic malignancy treated with chemotherapy within 12 months before baseline (C1D1).Xx_NEWLINE_xXMalignancies other than disease under study are excluded, except for any other malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigators and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on the currently targeted malignancy (MM).Xx_NEWLINE_xXHistory of another primary malignancy that has not been in remission for at least 2 years.Xx_NEWLINE_xXConcurrent malignancy requiring active therapyXx_NEWLINE_xXHas a known additional malignancy that is progressing or has required active treatment within the past 3 yearsXx_NEWLINE_xXPresence of a concurrent active, incurable malignancy that may alter the outcome of the treatment for disease under treatment as determined by the treating physicianXx_NEWLINE_xXMalignancy within the last 3 yearsXx_NEWLINE_xXHistory of any malignancy within the last 6 months except for those specified in this protocol and low-grade malignancies not requiring active treatment.Xx_NEWLINE_xXPrior malignancy in past 2 years or as identified in Section 7.2 of this protocolXx_NEWLINE_xXPatients must not have a concurrent active malignancy for which they are receiving treatmentXx_NEWLINE_xXKnown active malignancy as determined by treating medical and radiation oncologist.Xx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXPatient must have hematologic malignancy that meets institutional eligibility requirements for cord blood transplantXx_NEWLINE_xXHistory of concurrent malignancy requiring active therapy or prior history of another malignancy within 5 years.Xx_NEWLINE_xXChemotherapy-naive patients (for this malignancy)Xx_NEWLINE_xXPatients with LVEF =< 40% documented from treatment with anthracyclines for any malignancy at any dose at any time without evidence of other causes of cardiomyopathyXx_NEWLINE_xXPatients receiving any other standard or investigational treatment for their hematologic malignancyXx_NEWLINE_xXPatients with a history of another malignancy within 5 years of study enrollmentXx_NEWLINE_xXPatients may have received chemotherapy or radiation for a previous, curatively treated non-HNSCC malignancy, provided at least 2 years have elapsed without evidence of recurrenceXx_NEWLINE_xXSubjects with active other malignancy diagnosed in the past 3 years (excepting in situ tumors)Xx_NEWLINE_xXUncontrolled prior invasive malignancy, excluding the current diagnosisXx_NEWLINE_xXIndividuals with a history of a previous malignancy are ineligible; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolledXx_NEWLINE_xXKnown past or current malignancy other than inclusion diagnosis, except for:Xx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatment or that may interfere with interpretation of response evaluation, in the judgment of the investigatorXx_NEWLINE_xXHave active malignancy with the exception of nonmelanoma skin cancer. Subjects who have had a hematopoietic stem cell transplant (HSCT) and who experience relapse or progression of the malignancy as per investigator's opinion are not to be enrolled.Xx_NEWLINE_xXBilateral breast malignancyXx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXHistory of other malignancy within 2 years prior to screeningXx_NEWLINE_xXPatient must not have a concurrent active malignancy for which they are receiving treatment (other than myelodysplastic syndromes [MDS])Xx_NEWLINE_xXHistory of prior invasive rectal malignancy, regardless of disease-free intervalXx_NEWLINE_xXOther active malignancy requiring concurrent interventionXx_NEWLINE_xXPrior chemotherapy for any malignancyXx_NEWLINE_xXPresence of malignancy other than the study indication under this trial within 3 years of study enrollmentXx_NEWLINE_xXHistory of prior malignancyXx_NEWLINE_xXActive other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatmentXx_NEWLINE_xXIndividuals with a history of a previous malignancy are ineligible; also, exposure to previous anti-neoplastic treatment may alter the ability to tolerate or respond to the agents utilized in this protocol; exception: individuals with a previous malignancy treated with surgery only (no chemotherapy or radiotherapy) more than 5 years prior to registration may be enrolledXx_NEWLINE_xXHistory of prior malignancy, with the exception of the following:Xx_NEWLINE_xXMalignancy treated with curative intent and with no evidence of active disease present for more than 3 years prior to screening and felt to be at low risk for recurrence by treating physicianXx_NEWLINE_xXPatients who have a history of any hematopoietic malignancyXx_NEWLINE_xXDiagnosed or treated for another malignancy =< 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. \r\n* NOTE: Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXOther malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entryXx_NEWLINE_xXPatient has a concurrent advantage active malignancy under treatmentXx_NEWLINE_xXPatients must have had verification of the malignancy at relapse, including immunophenotyping to confirm diagnosisXx_NEWLINE_xXOther malignancy requiring active treatmentXx_NEWLINE_xXConcurrent diagnosis of another malignancy if either systemic treatment or surgery is expected to be required within 2 years from study entryXx_NEWLINE_xXPatient has another active malignancyXx_NEWLINE_xXAny active secondary malignancyXx_NEWLINE_xXConcurrent malignancy other than the solid tumor under investigation, requiring\n             active treatment.Xx_NEWLINE_xXPatients must have had histologic verification of the malignancy at original diagnosis or at the time of recurrenceXx_NEWLINE_xXSubjects who have an uncontrolled systemic malignancy that is not in remissionXx_NEWLINE_xXPatients with a history of prior malignancy are eligible provided they were treated with curative intent and have been disease free for the time period considered appropriate to not interfere with the outcome of this studyXx_NEWLINE_xXPatients must have had histologic verification of malignancy at original diagnosis or relapseXx_NEWLINE_xXUntreated or uncontrolled 2nd malignancyXx_NEWLINE_xXPatients who have an active 2nd malignancy requiring systemic treatmentXx_NEWLINE_xXSubjects must not have primary uveal or mucosal melanoma, history or evidence of melanoma associated with immunodeficiency states or history of other malignancy within the past 3 years.Xx_NEWLINE_xXIs being actively treated for another concurrent malignancy or is less than five years from completion of treatment for another malignancyXx_NEWLINE_xXCerebral/meningeal disease related to the underlying malignancy that has not been definitively treatedXx_NEWLINE_xXHistory of another malignancy, unless the candidate has been disease-free for at least 5 years.Xx_NEWLINE_xXPatient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active interventionXx_NEWLINE_xXPatients with a history of prior malignancy are eligible provided they were treated with curative intent and have been free of disease for the time period considered appropriate for cure of the specific cancer; for most diseases this time frame is 5 yearsXx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXThe participant has a concurrent active malignancy other than the following:Xx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancersXx_NEWLINE_xXSubjects with a history of another invasive malignancy ?3 years of study drug initiation.Xx_NEWLINE_xXPart 3: advanced solid tumor or hematologic malignancyXx_NEWLINE_xXHistory of prior malignancy except:Xx_NEWLINE_xXPrior malignancy except for any of the following:Xx_NEWLINE_xXKnown additional malignancy that is progressing or has required active treatment within the past 3 years.Xx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatment within the past 5 years.Xx_NEWLINE_xXRelapsed, progressing or persistent malignancy requiring withdrawal of systemic immune suppression.Xx_NEWLINE_xXKnown additional malignancy that required treatment or progressed in last 5 yearsXx_NEWLINE_xXHistory of other malignancy within the last 5 yearsXx_NEWLINE_xXPrevious malignancy confined and surgically resected (or treated with other modalities) with curative intent.Xx_NEWLINE_xXDiagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.Xx_NEWLINE_xXPrior treatment for lymphoid malignancy:Xx_NEWLINE_xXOther invasive malignancy within the past 3 years.Xx_NEWLINE_xXActive cerebral/meningeal disease related to the underlying malignancy.Xx_NEWLINE_xXHistory of another invasive malignancy that has not been in remission for at least 3 yearsXx_NEWLINE_xXPrevious or concurrent malignancy with the following exceptions:Xx_NEWLINE_xXA primary malignancy which has been completely resected and in complete remission for ? 5 yearsXx_NEWLINE_xXHave a concurrent malignancy or had another malignancy within 5 years (?5 years) of study enrollment.Xx_NEWLINE_xXHistory of tuberous sclerosis, lymphangioleiomyomatosis (LAM) or any active malignancyXx_NEWLINE_xXNon-squamous malignancy of the penisXx_NEWLINE_xXKnown history of another primary malignancy that has not been in remission for ?2 yearsXx_NEWLINE_xXEvidence within the last 2 years of another malignancy which required systemic treatmentXx_NEWLINE_xXEvidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXDiagnosed or treated for another malignancy within 3 years (5 years for sites in France) before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXPatients with another uncontrolled malignancy; patients with a previous malignancy, treated curatively and without evidence of disease relapse are eligibleXx_NEWLINE_xXHistory of malignancy other than pancreatic carcinoma within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or deathXx_NEWLINE_xXHistory of malignancy other than NSLCL within 5 years prior to screening with the exception of malignancies with negligible risk of metastasis or deathXx_NEWLINE_xXDiagnosed or treated for a malignancy other than AML within 5 years, or who were previously diagnosed with a malignancy other than AML and have any radiographic or biochemical marker evidence of malignancy. Note: Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy at any time are not excludedXx_NEWLINE_xXHistory of any other malignancy other than skin cancer, or low grade bladder cancer which has been completely resected, within the previous 2 years. Patients that have had curative treatment of a previous malignancy and no recurrence of that malignancy within the past 2 years will be allowed.Xx_NEWLINE_xXSubject has another active malignancy requiring concurrent intervention;Xx_NEWLINE_xXone or more of the following biomarkers of malignancy:Xx_NEWLINE_xXDiagnosed with another malignancy within the past 3 yearsXx_NEWLINE_xXHave prior malignancy active within the previous 2 years;Xx_NEWLINE_xXDose Expansion Phase only: diagnosis of any other malignancy within 2 years prior to registration.Xx_NEWLINE_xXHistory of a primary invasive malignancy not listed in the inclusion criteria, which has not been in remission for at least 3 years. The following are exempt from the 3 year limit:Xx_NEWLINE_xXPresence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancyXx_NEWLINE_xXHistory of other malignancy with the past 2 years with some exceptionsXx_NEWLINE_xXPrior malignancy in the last 5 years, unless curatively treated and recurrence free (few exceptions apply).Xx_NEWLINE_xXPrior malignancy.Xx_NEWLINE_xXSubject has a history of a malignancy (other than the disease under treatment in the study) within 5 years before first study treatment administrationXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXAny active malignancy (other than BRAF-mutated melanoma) or a previous malignancy within the past 3 yearsXx_NEWLINE_xXHistory of a prior invasive malignancy in past 5 yearsXx_NEWLINE_xXPatients with prior malignancy (other than AML and MDS/CMML) are eligible; however, the patient must be in remission from the prior malignancy and have completed all chemotherapy and radiotherapy at least 6 months prior to registration; except for AML and MDS treatment, all treatment related toxicities must have been resolved; NOTE: for patients with prior history of malignancy who have received anthracyclines or mediastinal/pericardial radiation in the past, the risk versus benefit of therapy should be weighed, particularly in the setting of receiving consolidation therapyXx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXHistory of other malignancy within the past 3 years with the following exceptions:Xx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease present for ? 3 years before enrollment and felt to be at low risk for recurrence by the treating physicianXx_NEWLINE_xXHistory of another primary invasive cancer, hematologic malignancy, or myelodysplastic syndrome that has not been in remission for at least 3 yearsXx_NEWLINE_xXCerebral/meningeal disease related to the underlying malignancyXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXThere is any evidence of other malignancy being present within the last three years;Xx_NEWLINE_xXOther active malignancyXx_NEWLINE_xXKnown additional malignancy that is progressing or has required active treatment within the past 3 years.Xx_NEWLINE_xXKnown additional malignancy that is progressing or has required active treatment within the past 3 years.Xx_NEWLINE_xXKnown additional malignancy that has progressed or has required active treatment in the last 3 years.Xx_NEWLINE_xXActive secondary malignancyXx_NEWLINE_xXPatient has a history of hematological malignancy within the last 5 years prior to study entryXx_NEWLINE_xXHave a previous malignancy within 5 years of study entry or a concurrent malignancy.Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resection.Xx_NEWLINE_xXPrior invasive malignancy unless disease-free for a minimum of 5 yearsXx_NEWLINE_xXHistory of another malignancy within 3 yearsXx_NEWLINE_xXPatient is < 5 years free of another primary malignancy, except: a) if the other malignancy is basal cell carcinoma or cervical carcinoma in situ or b) if the other primary malignancy is not considered clinically significant and is requiring no active interventionXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXKnown other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis)Xx_NEWLINE_xXother effectively treated malignancy that has been in remission for more than 5 years and is considered to be curedXx_NEWLINE_xXHave an active malignancy other than prostate cancer that requires therapyXx_NEWLINE_xXAny other malignancy requiring treatmentXx_NEWLINE_xXParticipants with a previous malignancy within the past 3 yearsXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before first dose of study drug or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXSubjects with known or suspected brain metastasis, or brain as the only site of disease are excluded with the following exceptions\r\n* Subjects with controlled brain metastasis (no radiographic progression at least 4 weeks following radiation and/or surgical treatment, off steroids for at least 4 weeks, and have no new or progressing neurological signs or symptoms) will be allowed\r\n* Subjects with a history of prior malignancy with the exception of carcinoma in situ of the cervix or other malignancy diagnosed > 2 years ago that has undergone potentially curative therapy with no evidence of disease for the last >= 2 years and that is deemed by the investigator to be at a low risk of recurrenceXx_NEWLINE_xXKnown past or current malignancy other than inclusion diagnosis, except for:Xx_NEWLINE_xXAny active malignancy within 3 years that may alter the course of esophageal cancer; (apparently cured localized malignancy or advanced, but indolent malignancy with significantly more favorable prognosis are allowed)Xx_NEWLINE_xXThe subject has had within 2 years before the start of study treatment evidence of another malignancy which required systemic treatmentXx_NEWLINE_xXInvasive malignancy other than melanoma at the time of enrollment or within 5 years prior to first dose of study treatmentXx_NEWLINE_xXSubjects with history of other malignancy within past 5 years (with exceptions)Xx_NEWLINE_xXNo active co-existing malignancy with life expectancy less than 12 months due to that malignancyXx_NEWLINE_xXPatient is < 3 years free of another primary malignancy except: if the other primary malignancy is not currently clinically neither significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ; existence of any other malignant disease is not allowedXx_NEWLINE_xXOther active, concurrent malignancy that requires ongoing systemic treatment or interferes with radiographic assessment of melanoma response as determined by the investigatorXx_NEWLINE_xXOther malignancy within the last 5 yearsXx_NEWLINE_xXAny other current or previous malignancy within 3 years except protocol allowed malignanciesXx_NEWLINE_xXPrior or current malignancy that does not require concurrent treatment;Xx_NEWLINE_xXSubject has been diagnosed with another malignancy that requires concurrent treatment or hepatic malignancy regardless of need for treatment.Xx_NEWLINE_xXAdvanced measurable malignancyXx_NEWLINE_xXPatients with another primary malignancy that has not been in remission for at least 3 years.Xx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXActive malignancy of metastatic potential other than the known carcinoid or pancreatic NET within the past three yearsXx_NEWLINE_xXOther malignancy within 5 years except for noninvasive malignanciesXx_NEWLINE_xXPatient has an active concurrent malignancy/life-threatening disease. If there is a history of prior malignancies/life-threatening diseases, the patient is to be disease free for at least 5 years. Patients with other prior malignancies less than 5 years before study entry may still be enrolled if they have received treatment resulting in complete resolution of the cancer and currently have no clinical, radiologic, or laboratory evidence of active or recurrent disease.Xx_NEWLINE_xXPatient has positive urine cytology for malignancy at Screening.Xx_NEWLINE_xXSubject has a history of a non-HCC malignancy with the following exceptions:Xx_NEWLINE_xXThe subject with a previous history of a noninvasive carcinoma is eligible if in the opinion of the investigator he/she has had successful curative treatment any time prior to Screening and requires no further therapy for the malignancy.Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXHistory of any other malignancyXx_NEWLINE_xXPatient has a concurrent active malignancy under treatmentXx_NEWLINE_xXPatients who have been continuously disease-free for any solid tumor malignancy >3 years prior to the time of enrollment.Xx_NEWLINE_xXHistory of another primary malignancyXx_NEWLINE_xXKnown additional malignancy that is progressing or requires active treatmentXx_NEWLINE_xXOther malignancy within 2 years prior to Day 1 of the study, except for those treated with surgical intervention only.Xx_NEWLINE_xXOther active malignancy requiring concurrent interventionXx_NEWLINE_xXConcurrent active malignancy under treatment except prostate or breast cancer undergoing treatment with hormonal therapyXx_NEWLINE_xXPatients with a history of any other malignancy will not be eligibleXx_NEWLINE_xXConcurrent second malignancy or past malignancy with > 30% estimated risk of relapse in next 5 years; EXCEPTIONS: non-melanotic skin cancer or carcinoma-in-situ of the cervix; NOTE: if there is a history or prior malignancy, patient must not be receiving active treatment for this malignancy cancerXx_NEWLINE_xXPrior malignancy active within the previous 3 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXHistory of hematologic or primary solid tumor malignancy, unless no evidence of that disease for 5 yearsXx_NEWLINE_xXPatients with a history within the last 3 years of another invasive malignancy.Xx_NEWLINE_xXConcurrent malignancy requiring active therapy \r\n* Patients with more than one type of lymphoma may be enrolled after discussion with the MSK principal investigatorXx_NEWLINE_xXHistory of other malignancy, which could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXanother primary malignancyXx_NEWLINE_xXPatient has an active concurrent malignancy requiring active therapyXx_NEWLINE_xXAny concurrent and/or other active malignancy that has required treatment within 2 years of first dose of study drug.Xx_NEWLINE_xXHistory of prior malignancy for which patient is receiving other specific treatment for their cancerXx_NEWLINE_xXIndividuals with a history of a different malignancy are ineligible except for the following circumstances: 1) individuals with a history of other malignancies are eligible as long as there is no evidence of metastases and life expectancy deemed > 2 yearsXx_NEWLINE_xXPatients must not have other active concurrent malignancyXx_NEWLINE_xXOther invasive malignancy within 2 yearsXx_NEWLINE_xXAny prior history of hematologic malignancy (other than CTCL) within past 5 yearsXx_NEWLINE_xXAnother primary malignancyXx_NEWLINE_xXConcurrent malignancy diagnosed within 6 months of entry to the studyXx_NEWLINE_xXHistory of other malignancy (not including the underlying malignancy that was the indication for transplant)Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy with evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXHistory of other primary malignancy (including myeloid malignancy, e.g., myelodysplastic syndrome), unlessXx_NEWLINE_xXOther malignancy curatively treated with no known active disease present and no systemic treatment administered for 3 years before the first dose of study drugXx_NEWLINE_xXPatients with a previous malignancy (other than the patients' known cancer) that were treated successfully and are disease-free for at least 3 years are allowedXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy with evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPresence of malignancy (other than the one treated in this study) which required systemic treatment within the past 3 yearsXx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXResearch participants with presence of other active malignancy; however, research participants with history of prior malignancy treated with curative intent in complete remission are eligibleXx_NEWLINE_xXPrior history of metastatic malignancyXx_NEWLINE_xXIndividuals with a history of other malignancies are eligible if they have been disease free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXOther malignancy within five years, except that the following may be eligible:Xx_NEWLINE_xXActively being treated for other malignancy; if there is a history of prior malignancy, patient must not be receiving other specific treatment for their cancerXx_NEWLINE_xXHistory of another active uncontrolled malignancy at the time of study enrollmentXx_NEWLINE_xXPrior malignancy except previously diagnosed and definitively treated more than 3 years prior to trial or whose prognosis is deemed good enough to not warrant surveillanceXx_NEWLINE_xXPatients must not have an active secondary malignancyXx_NEWLINE_xXHistory of another malignancy. Subjects with another malignancy are eligible if: (a) disease-free for 3 years, or (b) have a history of completely resected non-melanoma skin cancer, and/or (c) have an indolent second malignancy(ies).Xx_NEWLINE_xXDiagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is being enrolled prior to patient enrollmentXx_NEWLINE_xXNo other active malignancyXx_NEWLINE_xXHistory of malignancy other than HCC within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or deathXx_NEWLINE_xXActive morphologic relapse/progression of hematologic malignancy post transplantation.Xx_NEWLINE_xXHas history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 2 yearsXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone resectionXx_NEWLINE_xXActive concurrent malignancy requiring active therapyXx_NEWLINE_xXIndividuals with a history of a different malignancy and are on treatment for the malignancy or the malignancy is documented on screening or other imaging are ineligible; individuals with a history of other malignancies are eligible if they are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXSubjects must have an advanced hematologic malignancy including: Phase 1/ Dose escalation:Xx_NEWLINE_xXPresence of malignancy other than the study indication under this trial within 5 years of study enrollmentXx_NEWLINE_xXPatients with a concurrent malignancyXx_NEWLINE_xXDiagnosed and treated for another malignancy within 5 years before randomization or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXParticipants must not have a concurrent malignancy unless it can be adequately treated by non-chemotherapeutic intervention; participants may have a history of prior malignancy, provided that he/she has not had any chemotherapy within 365 days of study entry AND that life expectancy exceeds 5 years at the time of study entryXx_NEWLINE_xXConcurrent or prior malignancy except for the following:Xx_NEWLINE_xXPatients with more than one active malignancy at the time of enrollment.Xx_NEWLINE_xXHistory of another primary invasive malignancy that has not been in remission for at least 3 yearsXx_NEWLINE_xXCerebral/meningeal disease related to the underlying malignancyXx_NEWLINE_xXHistory of metastatic malignancy in the preceding 2 yearsXx_NEWLINE_xXConcurrent other malignancyXx_NEWLINE_xXPatients who have had a previous malignancy that is not in remissionXx_NEWLINE_xXActive concurrent malignancy requiring active therapyXx_NEWLINE_xXSubjects with another active malignancyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXOther invasive malignancy within 2 yearsXx_NEWLINE_xXStable primary malignancy for previous 3 monthsXx_NEWLINE_xXActive treatment/chemotherapy for another primary malignancy within the past 5 yearsXx_NEWLINE_xXThe subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXA concurrent second malignancy even if it does not require active therapy; patients with indolent B-cell malignancies will not be eligible; prior malignancy will be allowed as long as the patient is known to be free of disease for at least 3 yearsXx_NEWLINE_xXRelapse of primary hematologic malignancy that served as indication for HCTXx_NEWLINE_xXPrior malignancy active within past 3 years, except for locally curable cancersXx_NEWLINE_xXHave borderline malignancyXx_NEWLINE_xXNo malignancy (other than for which patient underwent transplant) which required radiotherapy or systemic treatment within the past 5 yearsXx_NEWLINE_xXBiopsy confirmed malignancy of the gynecologic tractXx_NEWLINE_xXThe participant has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXParticipants with history of another primary malignancy not in remission for at least 3 yearsXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before randomization or previously diagnosed with another malignancy and any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type were not excluded if they had undergone complete resection.Xx_NEWLINE_xXThe patient has a recently diagnosed active malignancy requiring therapyXx_NEWLINE_xXIndividuals with a history of a different active malignancy are ineligibleXx_NEWLINE_xXPatients with a prior malignancy will NOT be eligible for participation aside from the following exception:\r\n* Patients who have had any curatively treated malignancy and have been disease free without treatment for 1 year prior to study entry ARE eligible for participationXx_NEWLINE_xXPatients must have pathologically-confirmed malignancyXx_NEWLINE_xXSubjects with no additional active malignancy within the last 3 yearsXx_NEWLINE_xXTime since last therapy for treatment of underlying malignancy:Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXConcurrent active malignancy requiring immediate therapyXx_NEWLINE_xXPrior therapy for advanced malignancy with no current curative optionXx_NEWLINE_xXPatients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligibleXx_NEWLINE_xXNo active or co-existing malignancy (other than ALL or lymphoblastic lymphoma) with life expectancy less than 12 months due to that malignancyXx_NEWLINE_xXPresence of active malignancy from an organ system other than hematopoieticXx_NEWLINE_xXE 08. Prior malignancy.Xx_NEWLINE_xXKnown history of or concomitant malignancy likely to affect life expectancy in the judgment of the investigatorXx_NEWLINE_xXHistory of metastatic malignancy in the preceding 2 yearsXx_NEWLINE_xXActive other malignancy requiring treatment that would interfere with the assessments of response of the lymphoma to protocol treatmentXx_NEWLINE_xXDiagnosed with another primary malignancy in the past 3 yearsXx_NEWLINE_xXPatients who have had a previous malignancy that is not in remissionXx_NEWLINE_xXDiagnosis of another malignancy within 2 years before first dose of study treatment.Xx_NEWLINE_xXHistory of prior malignancy within 3 years; patients who are considered no evidence of disease (NED) from a malignancy may be considered on a case by case basisXx_NEWLINE_xXOther malignancy within the last 5 years (few exceptions apply);Xx_NEWLINE_xXAn active malignancy that requires concurrent interventionXx_NEWLINE_xXConcomitant malignancy;Xx_NEWLINE_xXReceiving any treatment for persistent, progressive or recurrent malignancy.Xx_NEWLINE_xXProgressive or recurrent malignancy defined other than by quantitative molecular assays.Xx_NEWLINE_xXHistory of another primary malignancy that has not been in remission for at least 3 yearsXx_NEWLINE_xXPrior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for 2 years.Xx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXIndividuals with a history of a different malignancy are ineligible except for the following circumstances: individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXInvasive or active malignancy in past 2 yearsXx_NEWLINE_xXRecurrence or progression of primary malignancy after HCTXx_NEWLINE_xXDiagnosis of malignancy must be confirmed by the department of pathology at the institution where the patient is enrolled prior to patient enrollmentXx_NEWLINE_xXPatients must have indications for treatment for their B cell malignancy at the time of enrollment on this trialXx_NEWLINE_xXOther active malignancyXx_NEWLINE_xXPatients with a prior malignancy allowed if > 5 years ago with no current evidence of diseaseXx_NEWLINE_xXDiagnosis of hematologic malignancy and at least one of the criteria as specified aboveXx_NEWLINE_xXPatients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible; patients with a prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligibleXx_NEWLINE_xXNo invasive tumors within the last 5 years unless confined to an organ (e.g. prostate or thyroid cancer) and treated with curative therapy (e.g. surgery and/or radiation); please note, there must be no evidence of the prior malignancy using standard criteria to evaluate the specific prior malignancyXx_NEWLINE_xXActive malignancy with the exception of any of the following:Xx_NEWLINE_xXCerebral/meningeal disease related to underlying malignancyXx_NEWLINE_xXHistory of other active malignancy within the prior 2 yearsXx_NEWLINE_xXSubjects with relapsed/persistent malignancy requiring rapid immune suppression withdrawal.Xx_NEWLINE_xXHas a history of a malignancy, unless potentially curative treatment has been completed, with no evidence of malignancy for 5 yearsXx_NEWLINE_xXConcurrent active malignancy requiring immediate therapyXx_NEWLINE_xXPatients with a history of other invasive malignancies are excluded if there is any evidence of other malignancy being present within the last 3 yearsXx_NEWLINE_xXPrior malignancy, unless treated with curative intent and with no evidence of active disease present for > 5 years before screeningXx_NEWLINE_xXConcurrent active malignancy other than AML requiring therapyXx_NEWLINE_xXPatients who have had a previous malignancy unless they are deemed by their treating physicians to be at low risk for recurrenceXx_NEWLINE_xXConcurrent malignancy other than SCLC. History of other malignancy is allowed as long as there is no evidence of active disease or need for treatment.Xx_NEWLINE_xXSubjects being actively treated for a secondary malignancy.Xx_NEWLINE_xXParticipant with evidence of recurrent malignancyXx_NEWLINE_xXPatients with active concurrent malignancy, other than superficial, non-invasive squamous cell carcinoma of the skin or uterine cervix, within the past three years; an active concurrent malignancy will be defined as one currently requiring cancer-directed treatment, or deemed by the treating physician as likely to require such treatment within a six-month period from time of screeningXx_NEWLINE_xXActive treatment for a secondary malignancyXx_NEWLINE_xXPatients with a concurrent active malignancy (with the exception of skin cancer)Xx_NEWLINE_xXAny history of another metastatic malignancyXx_NEWLINE_xXSecondary malignancy, with the exception of:Xx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXPatients with evidence of another malignancy (exclusive of a skin cancer that requires only local treatment);\r\n* Patients with prior malignancies diagnosed > 5 years ago without evidence of disease are eligible\r\n* Patients with prior malignancy treated < 5 years ago but have a life expectancy of > 5 years for that malignancy are eligibleXx_NEWLINE_xXPrior invasive malignancy of other histology currently requiring treatmentXx_NEWLINE_xXConcurrent active malignancy requiring systemic treatmentXx_NEWLINE_xXEvidence of another clinically or radiographically active invasive malignancy OR diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXHas active secondary malignancy that requires treatment.Xx_NEWLINE_xXPatients with another malignancy within the past 5 yearsXx_NEWLINE_xXUndergoing active treatment for a secondary malignancy.Xx_NEWLINE_xXActive malignancy other than the one for which the UCB transplant is being performed within 12 months of enrollment.Xx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease present for ?3 years before the first dose of study drug and with low risk of recurrence by treating physician.Xx_NEWLINE_xXActive malignancy besides HNSCC or primary skin basal cell carcinoma; (patients with a concomitant malignancy that has not progressed within 12 months of study entry are eligible)Xx_NEWLINE_xXSubjects with a history of recent (within 28 days) systemic therapy for their underlying malignancyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXConcomitant treatment with chemotherapeutic agents for diseases other than malignancyXx_NEWLINE_xXPatients with more than one type of active malignancy; an active malignancy is defined as one that is being treated with therapeutic intent and for which survival may be impacted, within 3 years of enrollmentXx_NEWLINE_xXAnother current or previous malignancy within 2 years of study entry unless approved by the sponsorXx_NEWLINE_xXCurrent or previous other malignancy within 2 years of study entry without sponsor approvalXx_NEWLINE_xXInvasive malignancy or history of invasive malignancy other than disease under study: any other invasive malignancy from which the subject has been disease-free for more than 2 years and, in the opinion of the principal investigator and GSK Medical Monitor, will not affect the evaluation of the effects of this clinical trial treatment on currently targeted malignancy, can be included in this clinical trial; Curatively treated non-melanoma skin cancer and any carcinoma-in-situ.Xx_NEWLINE_xXCholangiocarcinoma with extra-hepatic metastasis or concurrent non-solid malignancyXx_NEWLINE_xXthe malignancy has been in remission without treatment for ? 5 years prior to enrollment, orXx_NEWLINE_xXDiagnosis of an advanced solid tumor malignancy.Xx_NEWLINE_xXHistological or cytological evidence of malignancy.Xx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection; this does not preclude previous diagnosis of acute myeloid leukemia or myelodysplastic syndromeXx_NEWLINE_xXPatients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patientXx_NEWLINE_xXSubjects must have newly diagnosed (within 3 years), previously untreated prostate cancer without concurrent malignancyXx_NEWLINE_xXPatients with known concurrent malignancyXx_NEWLINE_xXHistory of another primary malignancy that has not been in remission for 3 yearsXx_NEWLINE_xXHistopathologically confirmed diagnosis of a metastatic non-hematologic malignancy.Xx_NEWLINE_xXSubjects being actively treated for a secondary malignancy.Xx_NEWLINE_xXFor the hematologic malignancy patients, blood count values cited above do not apply.Xx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; if the original histologic proof of\r\nmalignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)Xx_NEWLINE_xXFor disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXHistory of another malignancy within 2 years prior to starting study treatmentXx_NEWLINE_xXPrior history of other malignancy except:Xx_NEWLINE_xXOther currently active malignancyXx_NEWLINE_xXHistory of other primary malignancy requiring systemic treatment within 6 months of protocol enrollment; patients must not have another active malignancy requiring treatment; patients must not be receiving chemotherapy or immunotherapy for another cancerXx_NEWLINE_xXActive concurrent malignancy (except skin cancer)Xx_NEWLINE_xXOther active malignancyXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients have a history of any other malignancyXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients have a history of any other malignancyXx_NEWLINE_xXPatients must not have another, non-breast, active malignancy that requires treatmentXx_NEWLINE_xXHas a known additional malignancy that is progressing or requires active treatment.Xx_NEWLINE_xXPrevious diagnosis of another malignancy with any evidence of residual diseaseXx_NEWLINE_xXFor disease specific studies: the subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXHistory (within 2 years prior to first study drug administration) of another malignancy unless the malignancy was treated with curative intent and likelihood of relapse is small (<5% in 2 years in the judgment of the investigator).Xx_NEWLINE_xXPatients must have primary brain malignancy (histologically confirmed by surgical specimen or cerebral spinal fluid [CSF] cytology), or metastatic brain malignancy; if the patient has metastatic brain malignancy, there must be a histologic pathology report confirming the primary site of the cancer, as well as one of the following: confirmation by surgical specimen, CSF cytology, elevated tumor markers, or clinical evidence of CNS involvementXx_NEWLINE_xXIndividuals who have undergone transplant for hematologic malignancy are required to be in complete remission.Xx_NEWLINE_xXOther active primary malignancy requiring treatment or limiting survival to =< 2 years prior to registrationXx_NEWLINE_xXConcurrent active malignancy under treatment.Xx_NEWLINE_xXConfirmed diagnosis of advanced malignancy:Xx_NEWLINE_xXOther active malignancy that requires therapyXx_NEWLINE_xXCerebral/meningeal disease related to the underlying malignancy, unless definitively treated.Xx_NEWLINE_xXLung disease unrelated to underlying malignancy.Xx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXAny other current malignancyXx_NEWLINE_xXAny prior history of other hematologic malignancy besides FL or myelodysplasiaXx_NEWLINE_xXMalignancy treated with curative intent and with no known active disease present for ?5 years before the first dose of study drug and felt to be at low risk for recurrence by treating physician.Xx_NEWLINE_xXConfirmed malignancy.Xx_NEWLINE_xXPresence of an active secondary malignancy.Xx_NEWLINE_xXPatients with a completely treated prior malignancy with no evidence of disease for ?3 years are eligibleXx_NEWLINE_xXUncontrolled concurrent malignancyXx_NEWLINE_xXPatients with active secondary malignancy will not be eligibleXx_NEWLINE_xXPresence of radiographically measurable lymphadenopathy or extranodal lymphoid malignancyXx_NEWLINE_xXActive malignancy other than SCLC within the previous 5 yearsXx_NEWLINE_xXAdvanced solid tumor malignancyXx_NEWLINE_xXKnown past or current malignancy other than inclusion diagnosis, except for:Xx_NEWLINE_xXCurrent (within last month) use of chemotherapy for breast or other malignancyXx_NEWLINE_xXCurrent (within last 3 months) use of radiation for breast or other malignancyXx_NEWLINE_xXNo concurrent malignancy with a life expectancy of less than two years, or one that requires ongoing chemotherapeutic intervention at screeningXx_NEWLINE_xXPatients with prior invasive malignancy within two years of enrollment are excludedXx_NEWLINE_xXPrior treatment of any kind for this malignancyXx_NEWLINE_xXDoes not have any other active malignancy other than the one for which this transplant is indicatedXx_NEWLINE_xXNo other known active secondary primary malignancyXx_NEWLINE_xXNewly Diagnosed Secondary AML age <60 years and ?76 to 80 years, defined as having a history of an antecedent hematologic disorder (myelodysplastic syndromes [MDS], myeloproliferative disease [MPD]or history of cytotoxic treatment for non-hematologic malignancy)Xx_NEWLINE_xXPatient has any other active malignancy other than the one for which HCT is indicatedXx_NEWLINE_xXHistory of other malignancy that could affect compliance with the protocol or interpretation of resultsXx_NEWLINE_xXBeing actively treated for another concurrent malignancyXx_NEWLINE_xXAny other current malignancyXx_NEWLINE_xXHistory of another malignancy, some exceptions may apply.Xx_NEWLINE_xXHistory of malignancy other than ALL within 5 years prior to start of protocol-required therapy, except for adequately treated selected cancers without evidence of diseaseXx_NEWLINE_xXHistory of another active malignancy within the past 5 years, or any malignancy with a confirmed activating RAS mutation. The prospective RAS mutation testing is not required, however, if results of previous RAS testing are known, they must be used in assessing eligibility. Subjects with a history of completely resected non-melanoma skin cancer are eligible.Xx_NEWLINE_xXAnother active concurrent malignancy.Xx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXHistory of another malignancy in the previous 5 years, unless cured by surgery alone and continuously disease-freeXx_NEWLINE_xXThe subject has had another active malignancy within the past 3 years except for any cancer in situ that the Principal Investigator considers to be cured. Questions regarding the inclusion of individual subject should be directed to the Medical Monitor.Xx_NEWLINE_xXSevere dyspnea at rest due to complications of advanced malignancy or requiring current continuous oxygen therapyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years of enrollment, with the exception of in situ malignanciesXx_NEWLINE_xXPatients with active secondary malignancy will not be eligible unless approved by the principal investigator (PI)Xx_NEWLINE_xXFree of metastatic malignancy (other than MDS) for ?2 yearsXx_NEWLINE_xXNo history of any hematopoietic malignancyXx_NEWLINE_xXReceiving any other standard treatment for their hematologic malignancy.Xx_NEWLINE_xXPatients receiving active treatment or intervention for any other malignancy or patients who, at the Investigator's discretion, may require active treatment or intervention for any other malignancy within 8 months of starting study treatment.Xx_NEWLINE_xXOther current malignancy than the disease under studyXx_NEWLINE_xXHistory of documented adrenal dysfunction not due to malignancy.Xx_NEWLINE_xXThe subject has had evidence within 2 years of the start of study treatment of another malignancy which required systemic treatmentXx_NEWLINE_xXMalignancy OTHER than the BRAF mutant malignancy under study.Xx_NEWLINE_xXUncontrolled concurrent malignancy that would limit assessment of efficacy of cabozantinibXx_NEWLINE_xXOther active concomitant malignancy that warrants systemic therapyXx_NEWLINE_xXOther active concomitant malignancy that warrants systemic therapyXx_NEWLINE_xXConcurrent history of malignancy other than cervical cancer within 3 years of first planned dose of REGN2810, except for tumors with negligible risk of metastasisXx_NEWLINE_xXConcurrent malignancy or malignancy within 3 years prior to start of study treatmentXx_NEWLINE_xXDoes not have any other active malignancy other than the one for which this transplant is indicatedXx_NEWLINE_xXPatients who have a history of primary malignancy other than that being treated in this study, and currently requires active clinical intervention.Xx_NEWLINE_xXPatient has another concurrent invasive malignancy (aside from the malignancy for which the patient has received therapy for on the parental protocol).Xx_NEWLINE_xXHistory of another malignancy within the previous 5 years;Xx_NEWLINE_xXSubjects with a history of prior malignancy active within the previous 2 years except for locally curable cancers that have been apparently curedXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situXx_NEWLINE_xXMalignancy other than NSCLC within 5 years prior to randomization and evidence of any other disease that contraindicates the use of an investigational or SOC drugXx_NEWLINE_xXIs diagnosed or treated for another malignancy within 2 years before the first dose or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situXx_NEWLINE_xXAny other malignancy that requires active treatmentXx_NEWLINE_xXHistory of another primary malignancy that has not been in remission for at least 3 yearsXx_NEWLINE_xXKnown transformation to an aggressive B-cell malignancy.Xx_NEWLINE_xXHistologic or cytologic confirmation of a solid malignancyXx_NEWLINE_xXHistory of any other malignancy requiring active treatmentXx_NEWLINE_xXNo other currently active malignancy.Xx_NEWLINE_xXHistory of any hematopoietic malignancyXx_NEWLINE_xXConcurrent active malignancy.Xx_NEWLINE_xXThe patient has (or has had) previous or concomitant malignancies, except effectively treated malignancy that is considered by the investigator highly likely to have been cured.Xx_NEWLINE_xXOther active malignancy.Xx_NEWLINE_xXMalignancy other than nonmelanoma skin cancerXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXOther malignancy requiring active treatment at time of study entryXx_NEWLINE_xXPresence of another concurrent malignancy requiring treatmentXx_NEWLINE_xXPrevious or concurrent malignancy is not an exclusion provided that the other malignancy is considered under control and target lesions from melanoma are clearly defined for response assessmentXx_NEWLINE_xXEvidence of other concurrent active malignancyXx_NEWLINE_xXPatients diagnosed with or treated for another malignancy within 2 years prior to study enrollment or previously diagnosed with another malignancy and still having any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients with a pathologic diagnosis of malignancyXx_NEWLINE_xXA diagnosis of any hematologic or solid malignancyXx_NEWLINE_xXOther active, invasive malignancy requiring ongoing therapy or expected to require systemic therapyXx_NEWLINE_xXHistory of a primary bone malignancy involving the lumbar spineXx_NEWLINE_xXWith a hematological malignancyXx_NEWLINE_xXPatients must not have other active concurrent malignancyXx_NEWLINE_xXCurrent severe active systemic disease including active concurrent malignancyXx_NEWLINE_xXHas history of a diagnosed and/or treated hematologic or primary solid tumor malignancy, unless in remission for at least 5 years prior to randomizationXx_NEWLINE_xXSubject has other prior malignancy that is not in complete remission.Xx_NEWLINE_xXHistory of malignancy other than the underlying disease unless treated with a curative intent and/or no evidence of disease for at least 3 years (y) OR expected to be cured with SCTXx_NEWLINE_xXUntreated active, or inappropriately/inadequately treated breast malignancy, without surgical treatmentXx_NEWLINE_xXInvasive malignancy or history of invasive malignancy other than disease under study within the last two years except: Any other invasive malignancy for which the subject was definitively treated, has been disease-free for <=2 years and in the opinion of the principal investigator and GSK Medical Monitor will not affect the evaluation of the effects of the study treatment on the currently targeted malignancy, may be included in this clinical trial; and curatively treated non-melanoma skin cancer.Xx_NEWLINE_xXAre undergoing cancer treatment for another malignancyXx_NEWLINE_xXPatients may have a history of other prior malignancyXx_NEWLINE_xXRecurrent or progressive malignancy requiring anti-cancer therapyXx_NEWLINE_xXMetastatic malignancy of any kindXx_NEWLINE_xXMetastatic malignancy of any kindXx_NEWLINE_xXPatients with hematologic malignancy receiving care (chemotherapy, immunotherapy, targeted agents, bone marrow transplant, or other) for their hematologic malignancy at the Ohio State UniversityXx_NEWLINE_xXPatients without a diagnosis of a gynecologic malignancyXx_NEWLINE_xXPrimary malignancy for which the patient received transplant has been stable for 3 months prior to enrollment on studyXx_NEWLINE_xXHematologic malignancyXx_NEWLINE_xXSecondary malignancyXx_NEWLINE_xXHas no other active primary malignancy aside from prostate cancerXx_NEWLINE_xXHas other active primary malignancy aside from prostate cancerXx_NEWLINE_xXProgressive malignancyXx_NEWLINE_xXDiagnosis of a hormone responsive malignancyXx_NEWLINE_xXHave a diagnosed malignancyXx_NEWLINE_xXHistory of previous systemic chemotherapy unless given curatively for other malignancy now > 5 years without evidence of recurrenceXx_NEWLINE_xXPresence of any other concurrent, actively treated malignancyXx_NEWLINE_xXPresence of a concurrent, actively treated malignancyXx_NEWLINE_xXAdult patients with hematologic malignancy who underwent an allogeneic HCT at least 3 months prior to study enrollmentXx_NEWLINE_xXConcurrent malignancy or metastatic malignancy of any kindXx_NEWLINE_xXPatients with evidence of persistent or active malignancyXx_NEWLINE_xXPatient with a secondary malignancy who would be otherwise eligible for study, but for whom remission from the primary disease cannot be conclusively confirmed or for whom the chance of relapse of the primary disease is significantXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of solid tumor malignancy within 5 years prior to Step 2 registration; if the original histologic proof of malignancy is greater than 5 years, then pathological (i.e., more recent) confirmation is required (e.g., from a systemic metastasis or brain metastasis)Xx_NEWLINE_xXConcurrent or history of malignancyXx_NEWLINE_xXPatients diagnosed with a hematologic malignancyXx_NEWLINE_xXDiagnosis of malignancy treated with chemotherapy and/or radiation therapy at Seattle Children's Hospital (SCH)\r\n* New diagnosis of malignancy within 1-10 weeks of enrollment\r\n* New diagnosis of recurrent disease (after initial remission) or refractory disease at any time during therapyXx_NEWLINE_xXThere is histocytological confirmation of pleural malignancyXx_NEWLINE_xXParticipants must not have any other concurrent malignancyXx_NEWLINE_xXParticipants has a history of hematological malignancy within the last 5 years prior to study entryXx_NEWLINE_xXPatient has an active concurrent malignancy requiring active therapyXx_NEWLINE_xXPatient must be newly diagnosed (i.e., not relapsed) with any malignancyXx_NEWLINE_xXAny prior invasive malignancy within 5 years before randomizationXx_NEWLINE_xXAny non-invasive malignancy not treated with curative intent or with knownactive disease within 5 years before randomizationXx_NEWLINE_xXPathologically (histologically or cytologically) proven diagnosis of a non-hematopoietic malignancy other than small cell lung cancer and germ cell malignancy within 5 years of registration; if the original histologic proof of malignancy is greater than 5 years, then pathological confirmation is required (e.g. from extra- or intra-cranial disease)Xx_NEWLINE_xXSolid organ malignancy with documented bone metastasis by imagingXx_NEWLINE_xXAnother active malignancyXx_NEWLINE_xXMalignancy with bone instabilityXx_NEWLINE_xXPatients with active malignancy; patient undergoing active treatment for malignancy in the adjuvant setting are eligible; treatment can include chemotherapy, targeted therapy or anti-hormonal therapyXx_NEWLINE_xXPatients have a concurrent malignancyXx_NEWLINE_xXSubjects who have previously completed primary treatment for a gynecologic malignancyXx_NEWLINE_xXReceived a transplant at a consortium center for a hematologic malignancy or myelodysplasiaXx_NEWLINE_xXActive and uncontrolled relapse of malignancyXx_NEWLINE_xXPatients with evidence of recurrent malignancyXx_NEWLINE_xXActive hematologic malignancy (cancer that begins in blood-forming tissue, such as leukemia or lymphoma)Xx_NEWLINE_xXActive malignancy other than ovarian cancerXx_NEWLINE_xXActive malignancy, metastatic disease, or anyone undergoing treatment for malignancyXx_NEWLINE_xXEvidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms is permitted)Xx_NEWLINE_xXFOR THE 31 SUBJECTS ENROLLED IN YEAR 1: Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms is permitted)Xx_NEWLINE_xXConcurrent malignancy requiring active treatment with chemotherapy, immunotherapy, or radiationXx_NEWLINE_xXEvidence of hematologic malignancy or disease relapse post-transplant (stable mixed chimerisms are permitted)Xx_NEWLINE_xXWomen with an active malignancyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXPatients who have received chemotherapy for a malignancy in the past 5 yearsXx_NEWLINE_xXRPFNA criteria:\r\n* Cells suspicious for malignancyXx_NEWLINE_xXMetastatic malignancy of any kindXx_NEWLINE_xXOther current malignancy or metastatic malignancy of any kindXx_NEWLINE_xXPatients with a relapsed and/or refractory underlying hematologic malignancyXx_NEWLINE_xXSubjects may have a history of prior malignancy except for esophageal adenocarcinomaXx_NEWLINE_xXConcurrent malignancy or metastatic malignancy of any kindXx_NEWLINE_xXAny other current or previous malignancyXx_NEWLINE_xXAnother malignancy within 3 yearsXx_NEWLINE_xXNon-hematologic malignancy within prior three (3) years.Xx_NEWLINE_xXHistory of malignancy, including prior SCCHN primary tumors within 5 years prior to screening, with the exception of malignancies with a negligible risk of metastasis or deathXx_NEWLINE_xXSubject has had any other prior invasive malignancy, unless disease-free for a minimum of 3 years.Xx_NEWLINE_xXhistory of any other primary malignancy diagnosed within the past 5 yearsXx_NEWLINE_xXPatient must not have another active (within past 3 years) or concurrent malignancyXx_NEWLINE_xXEXCLUSION - HEALTHY VOLUNTEERS: Prior or current malignancyXx_NEWLINE_xXMalignancy other than current disease under studyXx_NEWLINE_xXRelapsed/persistent malignancyXx_NEWLINE_xXAny other current or previous malignancy within the past 5 yearsXx_NEWLINE_xXHave an active malignancy other than prostate cancer that requires therapyXx_NEWLINE_xXPatient's malignancy is consistent with well differentiated neuroendocrine (carcinoid) histologyXx_NEWLINE_xXMalignancy consistent with a neuroendocrine histologyXx_NEWLINE_xXPatients with a malignancy within the past 3 years for which study drugs or a prostatectomy is a contraindicationXx_NEWLINE_xXPatient has an active malignancy of metastatic potential other than the known NE tumor for the past 3 yearsXx_NEWLINE_xXSubjects must not have been treated with chemotherapy or radiation for another malignancy within the preceding 6 monthsXx_NEWLINE_xXPatients diagnosed with secondary hepatic malignancyXx_NEWLINE_xXBiopsy confirmed malignancy associated calcifications in at least one breastXx_NEWLINE_xXHistory of a prior malignancy within past 5 years are excluded unless they have been disease free for 3 or more yearsXx_NEWLINE_xXPrior systemic chemotherapy for rectal cancer; prior chemotherapy for another malignancy is allowable as long as it has been > 2 years since completion of therapy for previous malignancyXx_NEWLINE_xXPrior systemic chemotherapy for esophageal cancer; prior chemotherapy for another malignancy is allowable as long as it has been > 2 years since completion of therapy for previous malignancyXx_NEWLINE_xXConcurrent malignancy other than skin cancerXx_NEWLINE_xXIndividuals with a history of a different malignancy are ineligible except for the following circumstances; individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancyXx_NEWLINE_xXHas history of other active malignancy within 3 years prior to enrollment, except:Xx_NEWLINE_xXSubjects must not have another active invasive malignancy, with the following exceptions and notes:Xx_NEWLINE_xXHistory of malignancy that is in complete remission after treatment with curative intent is allowed.Xx_NEWLINE_xXOther active malignancy besides HCC within 3 years.Xx_NEWLINE_xXEvidence of active malignancy at the time of HCT or at any time since the HCT.Xx_NEWLINE_xXHistory of malignancy (other than the disease that required the HCT) within 5 years prior to screening.Xx_NEWLINE_xXHas a history of a previous additional malignancy unless potentially curative treatment has been completed with no evidence of malignancy for 5 yearsXx_NEWLINE_xXOther malignancy diagnosed or requiring treatment within the defined period with specific exceptionsXx_NEWLINE_xXPatients who have already started treatment for the current malignancyXx_NEWLINE_xXWomen with a history of a prior malignancyXx_NEWLINE_xXDiagnosis of malignant liver tumor; (pathological diagnosis of malignancy or at least one liver lesion seen on imaging that is suspicious for malignancy)Xx_NEWLINE_xXPatients malignancy consistent with well differentiated (carcinoid) neuroendocrine histologyXx_NEWLINE_xXActive other malignancy requiring treatment that would interfere with the assessments of this studyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease; patients with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resectionXx_NEWLINE_xXCurrent or recent treatment for any malignancy within the last one year, which may affect biomarkersXx_NEWLINE_xXEvidence of other active malignancy requiring treatmentXx_NEWLINE_xXHave a second primary malignancy or any history in any time frame of a prior malignancy.Xx_NEWLINE_xXPatients may have had a prior malignancyXx_NEWLINE_xXPresence of concurrent non-solid malignancyXx_NEWLINE_xXDiagnosed or treated for another malignancy within 2 years before administration of the first dose of study drug, or previously diagnosed with another malignancy and have any evidence of residual disease. Participants with nonmelanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.Xx_NEWLINE_xXScheduled for a lumpectomy for a breast malignancy.Xx_NEWLINE_xXCriteria 5, History of other malignancy within the past 5 years prior to enrollment with some exceptions, as outlined in the protocol.Xx_NEWLINE_xXA working diagnosis of malignancy in the liver, brain, H&N, or pelvisXx_NEWLINE_xXPrior malignancy, active within the last 3 years, except for locally curable cancers which have been apparently curedXx_NEWLINE_xXPrior or concurrent malignancy, except the following:Xx_NEWLINE_xXHistory of other malignancy within the past 3 yearsXx_NEWLINE_xXAt least ? 2 prior treatment regimens for the underlying malignancyXx_NEWLINE_xXConfirmed advanced solid tumor or hematologic malignancyXx_NEWLINE_xXOther malignancy with life expectancy < 1 year due to the other malignancyXx_NEWLINE_xXKnown other previous/current malignancy requiring treatment within ? 3 years except for liited disease treated with curative intentXx_NEWLINE_xXHistory of other malignancy within the past 5 years with the following exception: . malignancy treated with curative intent and with no known active disease present and has not received chemotherapy for > 5 years before enrollment and felt to be at low risk for recurrence by the treating physician.Xx_NEWLINE_xXHistory of gynecologic malignancy that is estrogen dependentXx_NEWLINE_xX